mechlorethamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1647	51-75-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: mustine mechlorethamine mustargen nitrogen mustard chlormethine mechlorethamine hydrochloride mechlorethamine HCl	A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA. Molecular weight: 156.05 Formula: C5H11Cl2N CLOGP: 1.20 LIPINSKI: 0 HAC: 1 HDO: 0 TPSA: 3.24 ALOGS: -0.67 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

mustine
mechlorethamine
mustargen
nitrogen mustard
chlormethine
mechlorethamine hydrochloride
mechlorethamine HCl

A biologic alkylating agent that exerts its cytotoxic effects by forming DNA ADDUCTS and DNA interstrand crosslinks, thereby inhibiting rapidly proliferating cells. The hydrochloride is an antineoplastic agent used to treat HODGKIN DISEASE and LYMPHOMA.

Molecular weight: 156.05
Formula: C5H11Cl2N
CLOGP: 1.20
LIPINSKI: 0
HAC: 1
HDO: 0
TPSA: 3.24
ALOGS: -0.67
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
March 15, 1949	FDA	RECORDATI RARE

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Application site pruritus	445.23	52.66	80	1758	3904	63483280
Application site pain	363.89	52.66	68	1770	4114	63483070
Application site erythema	329.28	52.66	64	1774	4771	63482413
Application site discolouration	235.36	52.66	37	1801	784	63486400
Application site irritation	207.38	52.66	37	1801	1713	63485471
Skin discolouration	162.30	52.66	55	1783	37773	63449411
Pruritus	157.21	52.66	108	1730	361345	63125839
Skin irritation	144.09	52.66	37	1801	9704	63477480
Erythema	117.11	52.66	69	1769	175682	63311502
Application site vesicles	116.16	52.66	22	1816	1413	63485771

Showing 1 to 10 of 17 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Application site pruritus	478.45	55.30	81	1934	1356	34953560
Application site erythema	419.88	55.30	78	1937	2258	34952658
Application site pain	363.85	55.30	67	1948	1841	34953075
Pruritus	202.70	55.30	116	1899	141865	34813051
Application site irritation	188.87	55.30	33	1982	662	34954254
Skin irritation	178.19	55.30	45	1970	5532	34949384
Application site vesicles	172.15	55.30	30	1985	592	34954324
Therapy non-responder	139.93	55.30	60	1955	39086	34915830
Erythema	121.94	55.30	71	1944	88709	34866207
Application site discolouration	120.92	55.30	20	1995	284	34954632

Showing 1 to 10 of 23 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Application site pruritus	914.85	43.92	158	3645	3652	79736933
Application site erythema	745.94	43.92	139	3664	4971	79735614
Application site pain	691.98	43.92	129	3674	4618	79735967
Application site irritation	402.20	43.92	70	3733	1674	79738911
Application site discolouration	334.05	43.92	54	3749	810	79739775
Pruritus	332.67	43.92	215	3588	394433	79346152
Skin irritation	301.82	43.92	76	3727	11164	79729421
Application site vesicles	273.33	43.92	49	3754	1391	79739194
Therapy non-responder	230.60	43.92	104	3699	92201	79648384
Erythema	220.59	43.92	135	3668	223155	79517430

Showing 1 to 10 of 37 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	L01AA05	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS ALKYLATING AGENTS Nitrogen mustard analogues
CHEBI has role	CHEBI:35610	antineoplastic agents
FDA EPC	N0000175558	Alkylating Drug
FDA MoA	N0000000236	Alkylating Activity
MeSH PA	D000477	Alkylating Agents
MeSH PA	D000970	Antineoplastic Agents
MeSH PA	D018906	Antineoplastic Agents, Alkylating
MeSH PA	D002619	Chemical Warfare Agents
MeSH PA	D007509	Irritants
MeSH PA	D009676	Noxae

Showing 1 to 10 of 11 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Chronic lymphoid leukemia, disease	indication	92814006
Chronic myeloid leukemia	indication	92818009	DOID:8552
Polycythemia vera	indication	109992005
Hodgkin's disease	indication	118599009
Non-Hodgkin's lymphoma	indication	118601006
Mycosis fungoides	indication	118618005
Malignant tumor of lung	indication	363358000
Primary cutaneous T-cell lymphoma	indication	400122007
Pericardial Malignant Effusions	indication
Peritoneal Malignant Effusions	indication

Showing 1 to 10 of 24 entries

Previous1 2 3Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	5.7	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.016% BASE	VALCHLOR	HELSINN	N202317	Aug. 23, 2013	RX	GEL	TOPICAL	8501819	March 7, 2026	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY
EQ 0.016% BASE	VALCHLOR	HELSINN	N202317	Aug. 23, 2013	RX	GEL	TOPICAL	7872050	July 8, 2029	ALKYLATING DRUG INDICATED FOR THE TOPICAL TREATMENT OF STAGE IA AND IB MYCOSIS FUNGOIDES-TYPE CUTANEOUS T-CELL LYMPHOMA IN PATIENTS WHO HAVE RECEIVED PRIOR SKIN DIRECTED THERAPY

Showing 1 to 2 of 2 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

Show entries

Search:

ID	Source
002630	NDDF
004816	NDDF
155036	RXNORM
1972	MMSL
29156002	SNOMEDCT_US
29634	MMSL
372692002	SNOMEDCT_US
387071000	SNOMEDCT_US
4017994	VANDF
4019808	VUID

Showing 1 to 10 of 26 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
VALCHLOR	HUMAN PRESCRIPTION DRUG LABEL	1	69639-120	GEL	0.01 g	TOPICAL	NDA	28 sections
VALCHLOR	HUMAN PRESCRIPTION DRUG LABEL	1	69639-120	GEL	0.01 g	TOPICAL	NDA	28 sections

Showing 1 to 2 of 2 entries

Previous1Next